GILEAD SCIENCES SL

AbbVie, a pharmaceutical firm with strong immunology and oncology portfolios, is compared against key competitors in the Biotechnology industry. The analysis reveals AbbVie's high Price to Earnings (64.53), Price to Book (50.28), and Price to Sales (6.22) ratios, suggesting a potentially overvalued stock. However, its high Return on Equity (18.4%), EBITDA ($5.0B), and gross profit ($10.26B) indicate strong profitability and operational efficiency. The company's low revenue growth (4.31%) compared to the industry average (28.79%) raises concerns about future performance.

Gilead's research program has achieved advancements once thought impossible over 30 years.

Managed access offers patients with serious conditions access to investigational medical products when no alternative therapies exist. Clinical trials are preferred for data on efficacy and safety. When trials are unavailable, individual patient use or expanded access protocols are considered. Risks and benefits of investigational products should be carefully considered.

FDA grants Gilead Sciences' Livdelzi (seladelpar) accelerated approval for treating PBC in adults intolerant or unresponsive to UDCA. Livdelzi, a PPAR delta agonist, showed significant improvement in liver disease markers and reduced pruritus in the RESPONSE study, with potential for continued approval pending further trials.

Our 35-year history of success drives us to innovate in virology, oncology, and inflammation, transforming global health challenges like HIV and hepatitis C, and poised for revolutionary therapies.

As a global company, we offer access and operate in many regions around the world.

Through open dialogue, partnerships, and awareness, we aim to remove barriers and improve clinical trial participation experiences.

Indian Patent Office to hear objections against Gilead Sciences' patent claims on HIV drug Lenacapavir, with concerns over affordable access and ending AIDS. Sankalp opposes, citing the drug's previously known compound status under India’s Patent Act. Experts argue for public health priority over pharma profits, challenging Gilead's monopoly to enable generic competition.

iTeos Therapeutics' mid-stage trial results show its drug, when combined with GSK's immunotherapy, shrank lung tumors in twice as many patients compared to GSK's therapy alone. The trial raised safety concerns due to three treatment-related deaths from immune-related inflammation. Despite previous failures of TIGIT-targeting drugs, iTeos' data could rekindle interest in the target, with further data expected to clarify the combination's impact on survival and disease progression.

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.